Technical Analysis for DBVTF - Dbv Techs Boulogne Bill

Grade Last Price % Change Price Change
grade D 18.52 82.37% 8.3650
DBVTF closed up 82.37 percent on Thursday, May 9, 2019, on 2 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Down
See historical DBVTF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Gapped Up Strength 0.00%
New 52 Week Closing Low Bearish 82.37%
Volume Surge Other 82.37%
NR7 Range Contraction 82.37%
Doji - Bullish? Reversal 82.37%
New 52 Week Low Weakness 82.37%
Gapped Down Weakness 82.37%

Older signals for DBVTF ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
Medicine Medical Specialties Biopharmaceutical Immunology Immunotherapy Allergy Vaccine Crohn's Disease Bordatella Pertussis Food Allergies Hemophilia A I Diabetes Peanut Allergy
Is DBVTF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 52.5
52 Week Low 10.155
Average Volume 46,307
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 39.4945
Average True Range 5.0257
ADX 0.0
+DI 31.8363
-DI 67.9008
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line -4.469
MACD Signal Line -1.3652
MACD Histogram -3.1038
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.5200
Resistance 3 (R3) 18.5200 18.5200 18.5200
Resistance 2 (R2) 18.5200 18.5200 18.5200 18.5200
Resistance 1 (R1) 18.5200 18.5200 18.5200 18.5200 18.5200
Pivot Point 18.5200 18.5200 18.5200 18.5200 18.5200
Support 1 (S1) 18.5200 18.5200 18.5200 18.5200 18.5200
Support 2 (S2) 18.5200 18.5200 18.5200 18.5200
Support 3 (S3) 18.5200 18.5200 18.5200
Support 4 (S4) 18.5200